Víctor Fernández

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz et al. · The Lancet · 2016 · 243 citations

Thrombosis, Cardiovascular Disease, Pharmacology +8

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study

Suzanne Oparil, Michael Melino, James Lee et al. · Clinical Therapeutics · 2010 · 151 citations

Non-pharmacological Intervention, Hypertension, Cardiovascular Disease +12

24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy

Joseph L. Izzo, Steven G. Chrysant, Dean J. Kereiakes et al. · Journal of Clinical Hypertension · 2011 · 37 citations · Full text

Hypertension, 24-Hour Efficacy, Triple Combination +12